ClinicalTrials.gg
Enrolling by invitationNCT05189717Updated Apr 5, 2022

A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of Adults

A Phase 1 interventional study of HRS-8080 tablets、SHR 6390 tablets、Abemaciclib、Everolimus in Metastatic or Local Advanced Breast Cancer of Patients, sponsored by Shandong Suncadia Medicine Co., Ltd.. Enrolling by invitation at 2 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-04-05.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
156
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 485 studies in Neoplasm Metastasis with a site in China — 222 open to participants now, 263 under way, 40 of them phase 3. Neoplasm Metastasis · China.

Planned enrollment
146th of 401
156 · median 90
Started
2022
with 44 others
Phase 1
93 of 485
47 open now
Primary completion
2024-10
later than 27 of 262 live
Registered
213th of 485
by date

Among the 485 studies in Neoplasm Metastasis with a site in China, this one is the 146th largest by planned enrollment of the 401 interventional ones that give a count, is one of 45 that started in 2022, is one of 93 in phase 1, reaches primary completion later than 27 of the 262 other live ones, and was the 213th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

222 of the 485 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:

217 more — sign in →

All 222 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 485 studies in Neoplasm Metastasis with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the tolerance, and safety of HRS-8080 tablets monotherapy and combined with other anti-cancer therapy for metastatic or local advanced breast cancer in adults. To explore the reasonable dosage of HRS-8080 tablets for metastatic or local advanced breast cancer.

03

Conditions studied

  • Metastatic or Local Advanced Breast Cancer of Patients

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. performance status score: 0-1;
  2. Histopathologically documented local advanced or breast cancer ;
  3. Female of not must the related requirement;
  4. During or after the last systematic therapy before enrolment, disease progression occurred with clinical or radiographical documentation;
  5. Adequate organ functions as defined;
  6. Ability to understand and voluntarily agrees to participate by giving written for the study.

Exclusion criteria

Exclusion Criteria:

  1. For the case of symptomatic visceral , the investigators judged that it was not suitable to use relevant treatment;
  2. patients with active (without medical control or with clinical symptoms), cancerous meningitis, spinal cord compression, or patients with a history of primary tumors of the central nervous system ;
  3. History of cardiovascular or cerebrovascular diseases;
  4. The subject has one of many factors affecting oral drugs;
  5. Active infection or fever with unknown cause > 38.5 °C;
  6. Active diseases, History of immunodeficiency, including positive serum test result and other acquired or congenital immunodeficiency diseases, or history of organ transplantation;
  7. Known history of allergy to study drug ingredients.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    Single Group

    Firstly Dose Escalation and Dose Expansion of HRS-8080 monotherapy should be conducted. After RP2D and MTD of the HRS-8080 monotherapy were confirmed, Dose Escalation and Dose Extension of HRS-8080 in combination with other anti-cancer treatment would be completed, including SHR 6390, or Abemaciclib, or Everolimus.

    Drug: HRS-8080 tablets、SHR 6390 tablets、Abemaciclib、Everolimus

Interventions

This study also gives Abemaciclib. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose

    The Maximum tolerated dose of HRS-8080 monotherapy or in combination with SHR-6390 / Abemaciclib / Everolimus

    Time frame: up to 28 days

  2. Recommended phase II dose

    The Recommended phase II dose of HRS-8080 monotherapy or in combination with SHR-6390 / Abemaciclib / Everolimus

    Time frame: up to 28 days

  3. Incidence and severity of adverse events (AEs)/serious adverse events (SAEs)

    Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Time frame: up to 30 days after the last dose

Secondary outcomes

  1. Cmax

    PK parameters of multiple doses of HRS-8080 monotherapy. HRS-8080 in combination therapy, SHR-6390, Abemaciclib and Everolimus.

    Time frame: 0.5 hour before first dose of first treatment period to the 0.5 hour before first dose of fifth treatment period

  2. Tmax

    PK parameters of multiple doses of HRS-8080 monotherapy. HRS-8080 in combination therapy, SHR-6390, Abemaciclib and Everolimus. etc.

    Time frame: 0.5 hour before first dose of first treatment period to the 0.5 hour before first dose of fifth treatment period

  3. AUC0-t

    PK parameters of multiple doses of HRS-8080 monotherapy. HRS-8080 in combination therapy, SHR-6390, Abemaciclib and Everolimus.

    Time frame: 0.5 hour before first dose of first treatment period to the 0.5 hour before first dose of fifth treatment period

  4. Cmax,ss

    PK parameters of multiple doses of HRS-8080 monotherapy. HRS-8080 in combination therapy, SHR-6390, Abemaciclib and Everolimus.

    Time frame: 0.5 hour before first dose of first treatment period to the 0.5 hour before first dose of fifth treatment period

  5. Tmax,ss

    PK parameters of multiple doses of HRS-8080 monotherapy. HRS-8080 in combination therapy, SHR-6390, Abemaciclib and Everolimus.

    Time frame: 0.5 hour before first dose of first treatment period to the 0.5 hour before first dose of fifth treatment period

  6. Cmin,ss

    PK parameters of multiple doses of HRS-8080 monotherapy. HRS-8080 in combination therapy, SHR-6390, Abemaciclib and Everolimus.

    Time frame: 0.5 hour before first dose of first treatment period to the 0.5 hour before first dose of fifth treatment period

  7. AUCss

    PK parameters of multiple doses of HRS-8080 monotherapy. HRS-8080 in combination therapy, SHR-6390, Abemaciclib and Everolimus.

    Time frame: 0.5 hour before first dose of first treatment period to the 0.5 hour before first dose of fifth treatment period

  8. Rac

    PK parameters of multiple doses of HRS-8080 monotherapy. HRS-8080 in combination therapy, SHR-6390, Abemaciclib and Everolimus.

    Time frame: 0.5 hour before first dose of first treatment period to the 0.5 hour before first dose of fifth treatment period

  9. ORR

    Objective Response Rate, Preliminary Efficacy endpoints of HRS-8080 monotherapy or in combination with SHR-6390, Abemaciclib or Everolimus in treatment of patients with metastatic or local advanced breast cancer

    Time frame: from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 8 months

  10. BOR

    Best Overall Response, Preliminary Efficacy endpoints of HRS-8080 monotherapy or in combination with SHR-6390, Abemaciclib or Everolimus in treatment of patients with metastatic or local advanced breast cancer

    Time frame: from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 8 months

  11. DoR

    Duration of response, Preliminary Efficacy endpoints of HRS-8080 monotherapy or in combination with SHR-6390, Abemaciclib or Everolimus in treatment of patients with metastatic or local advanced breast cancer

    Time frame: from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 8 months

  12. DCR

    Disease control rate, Preliminary Efficacy endpoints of HRS-8080 monotherapy or in combination with SHR-6390, Abemaciclib or Everolimus in treatment of patients with metastatic or local advanced breast cancer

    Time frame: from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 8 months

  13. PFS

    Progression-free survival, Preliminary Efficacy endpoints of HRS-8080 monotherapy or in combination with SHR-6390, Abemaciclib or Everolimus in treatment of patients with metastatic or local advanced breast cancer

    Time frame: from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 8 months

07

Study locations

2 sites
  • Fifth Medical Center of People's Liberation Army of China General Hospital
    Beijing, Beijing 100071, China
  • Jilin Cancer Hospital
    Changchun, Jilin 130012, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Oct 2024, 32 months after the start.

Of 287 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 32 months is below that.

Counting every sponsor, half of 497 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2021
First posted
Jan 12, 2022
StartActual
Feb 17, 2022
Primary completionEst.
Oct 31, 2024
CompletionEst.
Jul 31, 2025
Last update
Apr 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05189717
Responsible party
Sponsor
First posted
Jan 12, 2022
Start date
Feb 17, 2022
Primary completion
Oct 31, 2024 (estimated)
Completion
Jul 31, 2025 (estimated)
Last update
Apr 5, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-8080

Start the discussion